Median PFS of 22.2 Months: Fruquintinib Plus Sintilimab Earns Level I Recommendation in 2026 CSCO Guidelines for Second-Line RCC

At the 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting, where China's leading oncology experts gathered to chart the future of cancer care, one combination therapy stole the spotlight. Fruquintinib plus sintilimab—a pairing of a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) with a programmed death receptor-1 (PD-1) inhibitor—has delivered a median progression-free survival (PFS) of 22.2 months in second-line treatment of advanced renal cell carcinoma (RCC), a figure that underscores both the drug's efficacy and the shifting landscape of kidney cancer therapy in China.

The results carry weight beyond the conference hall. On May 21, 2026, China's National Medical Products Administration (NMPA) officially approved the fruquintinib-sintilimab combination for patients with locally advanced or metastatic RCC who previously failed VEGFR-TKI therapy and had not received prior PD-1 or PD-L1 inhibitor treatment. Building on that regulatory milestone, the newly updated 2026 CSCO Renal Cancer Diagnosis and Treatment Guidelines elevated the combination to a Level I Recommendation with Grade 1A evidence for second-line treatment in this patient population—a designation that effectively enshrines the regimen as a standard of care.

For Innovent Biologics, Inc., the Suzhou-based developer of sintilimab (marketed as Tyvyt®), the dual validation represents a strategic win. The company's flagship PD-1 inhibitor now anchors a combination approach that addresses a long-standing gap in China's RCC treatment arsenal.

Filling a Void in Second-Line RCC

Despite the proliferation of target-immune combination therapies in recent years, treatment options for RCC patients after first-line VEGFR-TKI failure have remained stubbornly limited. The clinical reality was stark: patients who progressed on initial TKI therapy faced a narrow menu of second-line choices, many with modest efficacy profiles.

The FRUSICA-2 trial, a phase 2/3 randomized, open-label, active-controlled study presented at the 2025 European Society for Medical Oncology (ESMO) Congress (Abstract 4531), directly confronted this unmet need. The trial compared fruquintinib plus sintilimab against axitinib or everolimus monotherapy in the second-line setting, delivering the 22.2-month median PFS that now underpins the CSCO guideline upgrade.

The evidence strength—Grade 1A, the highest tier in CSCO's classification system—signals robust data from randomized controlled trials. For oncologists navigating treatment decisions, this designation removes ambiguity: the combination should be considered first among second-line options for eligible patients.

A Domestic Combination for Chinese Patients

The approval and guideline inclusion carry particular significance for China's oncology ecosystem. Both fruquintinib and sintilimab are domestically developed therapies, and their combination represents what Innovent describes as a homegrown "target-immune" approach to RCC—a pairing that enriches the local evidence base for second-line treatment while reducing reliance on imported alternatives.

The patient population addressed is specific: those who failed prior VEGFR-TKI therapy but have not yet received immune checkpoint inhibitors. This sequencing matters. The combination's efficacy in this defined cohort suggests that timing of immunotherapy introduction—after TKI failure but before prior immune exposure—may optimize outcomes.

The updated CSCO guidelines now position fruquintinib plus sintilimab alongside other second-line strategies for metastatic or unresectable clear cell RCC, offering clinicians a validated domestic option in a treatment algorithm that previously leaned heavily on international regimens.

Innovent's Expanding Footprint

Founded in 2011, Innovent Biologics has grown into one of China's most prolific biopharmaceutical developers. The company now markets 20 approved products spanning oncology, autoimmune diseases, metabolic disorders, and ophthalmology. Its pipeline includes one product under NDA review, five candidates in registration or pivotal clinical trials, and 20 additional programs in earlier-stage development.

The company's strategic collaboration portfolio reads as a who's who of global pharma: Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, among others, with more than 30 partnership agreements in place. Sintilimab, licensed to Eli Lilly for markets outside China (where it is marketed as Tyvyt), remains Innovent's crown jewel in the domestic oncology franchise.

Beyond commercial metrics, Innovent has built an extensive patient assistance infrastructure. The company reports that its drug donation programs have benefited over 200,000 patients, with cumulative donations valued at 4 billion RMB (approximately $560 million USD). The stated mission—"developing high-quality biologics that ordinary people can afford"—reflects a pricing philosophy that has helped the company gain traction in China's value-conscious healthcare system.

What Comes Next

The CSCO guideline upgrade and NMPA approval mark a inflection point for the fruquintinib-sintilimab combination, but questions remain. How will the regimen perform in broader, real-world populations beyond the controlled trial setting? And as immunotherapy combinations continue to proliferate in RCC, will the specific sequencing—TKI first, then target-immune—prove durable as a treatment paradigm?

For now, the 22.2-month median PFS offers a compelling answer to a question that has long vexed oncologists: what to do when first-line TKI therapy fails in advanced RCC. The combination of a domestic PD-1 inhibitor with a homegrown TKI, validated by phase 3 data and enshrined in national guidelines, represents more than a clinical option—it signals a maturation of China's biopharmaceutical innovation capacity.

The FRUSICA-2 data, presented at ESMO 2025 and now codified in the 2026 CSCO guidelines, may well define second-line RCC treatment in China for years to come. Whether this domestic combination can replicate its success in international markets remains to be seen—but for Chinese patients and oncologists, the answer to "what's next" after TKI failure has never been clearer.